Press Releases

 
Press Releases
  Date Title View
Sep 21, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656...
Sep 6, 2016
Appointment of Two Executives to Support Advancement of Product Pipeline: Christine Boisclair Named Vice President, Regulatory Affairs, and Scott Weintraub Named Vice President, Commercial and Product Strategy LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ...
Sep 1, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2016 Healthcare Conference on September 8, 2016 at 2...
Aug 9, 2016
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016. "Concert has made significant progress with our pipeline of multiple ...
Aug 2, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discus...
Jul 6, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 13, 2016, at 2:30 p.m. EDT at Le Parker Meridien in New York City. A live w...
Jun 10, 2016
Findings Confirmed Superior Pharmacokinetic Profile Relative to Kalydeco LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ascending dose trial of CTP-656, a next generation CFTR potentiator bein...
May 19, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for which there are currently no approved treatments. CTP-5...
May 17, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The UBS 2016 Global Healthcare Conference on May 24, 2016 at 8:00 a.m. EDT in N...
May 5, 2016
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016. "We are continuing to build a diverse pipeline based on our deuterium ...
FirstPrevious
3
...
NextLast
= add release to Briefcase